United States - English - NLM (National Library of Medicine)

foxland pharmaceuticals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), pyridoxal phosphate anhydrous (unii: f06sge49m6) (pyridoxal phosphate anhydrous - unii:f06sge49m6), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), methylcobalamin (unii: br1sn1js2w) (methylcobalamin - unii:br1sn1 - trinaz tablets are contraindicated in patients with a known hypersensitivity to any of the ingredients. do not take this product if you are presently taking mineral oil, unless directed by a doctor.

United States - English - NLM (National Library of Medicine)

foxland pharmaceuticals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), methylcobalamin (unii: br1sn1js2w) (methylcobalamin - unii:br1sn1js2w), biotin (unii: 6so6u10h04) - this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

United States - English - NLM (National Library of Medicine)

foxland pharmaceuticals, inc. - lactobacillus acidophilus (unii: 1prr1v42v5) (lactobacillus acidophilus - unii:1prr1v42v5), bifidobacterium animalis lactis (unii: 5307v7xw8i) (bifidobacterium animalis lactis - unii:5307v7xw8i) - zelac capsules is an orally administered prescription probiotic formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required, and maintenance of good health is needed.

United States - English - NLM (National Library of Medicine)

edgemont pharmaceuticals, llc - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 60 mg - fluoxetine is indicated for the treatment of: the use of maois intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine is contraindicated because of an increased risk of serotonin syndrome. the use of fluoxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.6) and warnings and precautions (5.2)] . starting fluoxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration ( 2.7 ) and warnings and precautions (5.2 )] . the use of fluoxetine is contraindicated with the following: pimozide and thioridazine prolong the qt interval. fluoxetine can increase the levels of pimozide and thioridazine through inhibition of cyp2d6. fluoxetine can also prolong the qt interval. pregnancy category c —fluoxetine should be used during pregnancy

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine oral solution usp is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine oral solution usp is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine defic

European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuclide imaging - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.4).

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology ). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient.  levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.

Ireland - English - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium nitrite - solution for injection - 30 milligram(s)/millilitre - sodium nitrite

Ireland - English - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium nitrite - solution for injection - 30 milligram(s)/millilitre - sodium nitrite

Ireland - English - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium thiosulfate - solution for injection - 250 milligram(s)/millilitre - antidotes; thiosulfate